{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:42:25Z","timestamp":1794512545302,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL), defined as del(17p) and\/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK), had poorer prognosis with chemoimmunotherapy. Bruton tyrosine kinase inhibitors (BTKis) have demonstrated benefit in higher-risk patient populations with CLL in individual trials. To better understand the impact of the second-generation BTKi acalabrutinib, we pooled data from 5 prospective clinical studies of acalabrutinib as monotherapy or in combination with obinutuzumab (ACE-CL-001, ACE-CL-003, ELEVATE-TN, ELEVATE-RR, and ASCEND) in patients with higher-risk CLL in treatment-naive (TN) or relapsed\/refractory (R\/R) cohorts. A total of 808 patients were included (TN cohort, n\u00a0= 320; R\/R cohort, n\u00a0= 488). Median follow-up was 59.1\u00a0months (TN cohort) and 44.3\u00a0months (R\/R cohort); 51.3% and 26.8% of patients in the TN and R\/R cohorts, respectively, remained on treatment at last follow-up. In the del(17p)\/TP53m, uIGHV, and CK subgroups in the TN cohort, median progression-free survival (PFS) and median overall survival (OS) were not reached (NR). In the del(17p)\/TP53m, uIGHV, and CK subgroups in the R\/R cohort, median PFS was 38.6\u00a0months, 46.9\u00a0months, and 38.6\u00a0months, respectively, and median OS was 60.6\u00a0months, NR, and NR, respectively. The safety profile of acalabrutinib-based therapy in this population was consistent with the known safety profile of acalabrutinib in a broad CLL population. Our analysis demonstrates long-term benefit of acalabrutinib-based regimens in patients with higher-risk CLL, regardless of line of therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011307","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T18:07:28Z","timestamp":1713550048000},"page":"3345-3359","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Acalabrutinib-based regimens in frontline or relapsed\/refractory higher-risk CLL: pooled analysis of 5 clinical trials"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"2Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"3Division of Experimental Oncology, Universit\u00e0 Vita-Salute San Raffaele, Milan, Italy"},{"name":"4Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"5The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"6Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"7Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"8City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-7531","authenticated-orcid":false,"given":"Paulo","family":"Miranda","sequence":"additional","affiliation":[{"name":"9AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Shahkarami","sequence":"additional","affiliation":[{"name":"10AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Butturini","sequence":"additional","affiliation":[{"name":"10AstraZeneca, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8251-6163","authenticated-orcid":false,"given":"Ugochinyere","family":"Emeribe","sequence":"additional","affiliation":[{"name":"9AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"25","key":"2024070912510694600_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2024070912510694600_bib2","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024070912510694600_bib3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"2024070912510694600_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"34","key":"2024070912510694600_bib5","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10232","key":"2024070912510694600_bib6","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"2024070912510694600_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"31","key":"2024070912510694600_bib8","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase 3 trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024070912510694600_bib9","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024070912510694600_bib10","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2024070912510694600_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"2024070912510694600_bib12","unstructured":"Wendtner\n              C\n            , Al-SawafO, BinderM, . Chronische Lymphatische Leuk\u00e4mie (CLL). 2023. Accessed 13 July 2023. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll\/@@guideline\/html\/index.html."},{"issue":"1","key":"2024070912510694600_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.122.001116","article-title":"Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent Bruton tyrosine kinase inhibitors","volume":"384","author":"Podoll","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"24","key":"2024070912510694600_bib14","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-na\u00efve chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2024070912510694600_bib15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2024070912510694600_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus obinutuzumab in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov"},{"issue":"12","key":"2024070912510694600_bib17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024070912510694600_bib18","first-page":"119","article-title":"Approximate is better than \"exact\" for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"issue":"4","key":"2024070912510694600_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"2024070912510694600_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"S3","key":"2024070912510694600_bib21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/01.HS9.0000969460.15364.af","article-title":"Zanubrutinib (zanu) vs bendamustine\u00a0+ rituximab (BR) in patients (pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): extended follow-up of the SEQUOIA study [abstract]","volume":"7","author":"Munir","year":"2023","journal-title":"HemaSphere"},{"issue":"S2","key":"2024070912510694600_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hon.3163_154","article-title":"Zanubrutinib (zanu) versus bendamustine\u00a0+ rituximab (BR) in patients (pts) with treatment-na\u00efve (TN) CLL\/SLL: extended follow-up of the SEQUOIA study [abstract","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"2024070912510694600_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy [abstract]","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024070912510694600_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024070912510694600_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2019.239947","article-title":"Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study","volume":"106","author":"Leeksma","year":"2021","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3345\/2233973\/blooda_adv-2023-011307-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3345\/2233973\/blooda_adv-2023-011307-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:51:28Z","timestamp":1720529488000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3345\/515785\/Acalabrutinib-based-regimens-in-frontline-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011307","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}